Share This
Create Your Own Business Intelligence Website
Input the stock code or the company name     Search  

<02196.HK> - Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

 Basic Datum
Company name Lot P/E P/B EPS DPS
FOSUN PHARMA 500 17.23 0.7189 0.9866 0.296
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 Company Rating
Date Broker Company name Rating Target
05-02 G.Sachs  FOSUN PHARMA 20.07
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
2022-04-27 復星醫藥(2196)今年首季純利按年大幅下跌45.4%,至4.62億元人民幣,季內表現主要受累於旗下投資BioNTech(美:BNTX)等金融資產的股價下跌。
2022-04-27 截至今年3月底,復必泰在港澳台累計接種逾2400萬劑疫苗。據報道,中國擬考慮引入復必泰疫苗,復星醫藥昨日股價升逾7%,收報34.55港元。
2022-04-27 復星醫藥首季收益主要受惠於mRNA新冠疫苗復必泰、注射用曲妥珠單抗「漢曲優」、馬來酸阿伐曲泊帕片「蘇可欣」、肝素系列製劑等產品的增長貢獻。
2022-04-27 復星醫藥上季已獲許可,向中低收入的國家供應默沙東研發的新冠藥物Molnupiravir、輝瑞新冠藥物Nirmatrelvir等。旗下在上海建設的移動式方艙實驗室,也在今年3月正式啟動檢測。
2022-04-27 復星醫藥自研的新冠病毒抗原檢測試劑在本月初於中國境內獲批上市。此前,該產品已通過歐盟CE認證、完成德國BfArM註冊,獲列入歐盟衛生安全委員會HSC Common List(歐盟通用白名單)。
 Top Gain / Loss Show All Charts 
Name Updated Value Change Change %
FOSUN PHARMA 05-08 10:59 12.94  12.94  ∞%

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.